Here's the short version. The cited studies do not establish this pair. Tesamorelin has approved Egrifta formulations for one HIV-related condition. Ipamorelin is unapproved. An ordinary compounded blend does not qualify for the relevant US exemptions [2].
| Tesamorelin | Ipamorelin | |
|---|---|---|
| What it is | A growth-hormone-releasing hormone analog; a biologic since March 23, 2020 | A ghrelin-receptor agonist (a growth hormone secretagogue) |
| FDA status | Approved as Egrifta SV and Egrifta WR for HIV-associated lipodystrophy [7] | Never approved |
| Compounding | Not eligible under 503A or 503B [2] | No 503A route; FDA keeps ipamorelin acetate in Category 2 of its 503B list [6] |
| Strongest human evidence | Trials of 412 and, pooled, 806 adults with HIV: deep belly fat about 15% lower than placebo at 26 weeks [9] | One phase 2 trial after bowel surgery: no significant benefit [10] |
| Combination evidence | Not established in cited studies | Not established in cited studies |
| Ordinary prescription route | Egrifta, by prescription | No approved or qualifying compounded product |
They raise growth hormone through two different switches
Tesamorelin is a man-made version of growth-hormone-releasing hormone, approved as Egrifta. Ipamorelin is an unapproved drug that acts on the ghrelin receptor, a separate route to the same gland. Both push the pituitary to release growth hormone.
That difference is the whole sales pitch for pairing them: two switches instead of one. A pitch isn't a result, though, and the human record for each looks very different.
- Tesamorelin: two phase 3 trials in adults with HIV cut deep belly fat about 15% against placebo at 26 weeks [8].
- Ipamorelin: in healthy men given it by vein, it produced one short growth-hormone pulse peaking at about 40 minutes, with a half-life near two hours [12].
- Ipamorelin's selling point: in rats and pigs, it raised growth hormone without raising the stress hormones ACTH and cortisol [11]. That's animal data.
- Ipamorelin patient trial: after bowel surgery, 114 people. It didn't significantly speed recovery, 25.3 hours to a first solid meal versus 32.6 on placebo [10].
The cited trials do not establish a combination regimen
The cited primary studies did not give both. Anything you read about how the pair works together is reasoning from how each one works alone.
That reasoning cuts both ways. Two growth-hormone signals could mean a bigger hormone response. It could also mean more of the side effects that come with one. Without a trial, nobody can tell you which, or how much.
A blend of the two can't come from a legitimate pharmacy
Egrifta can't be compounded since March 23, 2020, and ipamorelin has no 503A route, so a compounded blend of the two has no legal basis. Each half fails on its own.
Tesamorelin moved to the biologics framework on that date, and biologics on FDA's transition list lost the compounding exemptions [3]. Ipamorelin went before FDA's compounding advisory committee on October 29, 2024. Asked whether to add it to the list of substances pharmacies may compound, the committee voted 0 yes, 12 no, with 1 abstention, for both forms [4].
Ipamorelin is absent from the current May 2026 503A nomination categories [1]. FDA reviewers also identified no applicable USP monograph or approved-drug component basis for ordinary 503A compounding [5]. FDA keeps ipamorelin acetate in Category 2 of its 503B list, the outsourcing-facility side [6]. The full status of each is on tesamorelin's legal status page and ipamorelin's legal status page.
The Egrifta label identifies risks on tesamorelin alone
The label warns of high IGF-1, fluid retention, blood-sugar problems and allergic reactions. It also rules the drug out in active cancer and pregnancy [7].
- IGF-1: tesamorelin raises it, and the effects of long-term high levels are unknown. Prescribers check it and may stop the drug.
- Fluid retention: swelling, joint pain and carpal tunnel syndrome.
- Blood sugar: HbA1c reached 6.5% or higher in 5% on the drug versus 1% on placebo by week 26.
- Allergy: rash, itching, flushing or hives in 4% in clinical trials.
- Who shouldn't take it: people with active cancer, pituitary problems from surgery, radiation or injury, or who are pregnant.
Ipamorelin brings its own signal. In its bowel-surgery trial, more people on ipamorelin had high blood sugar at discharge, 14.3% versus 8.6% on placebo, FDA's reviewers noted. Two people on ipamorelin died after surgical complications; FDA said it was unclear whether the drug played a part [5].
Put the two next to each other and the overlap is plain: blood sugar shows up on both lists. Adding a second growth-hormone drug could push IGF-1 higher still. That's reasoning, not data, and it's exactly why a prescriber, not a menu, should make the call.
If someone offers you the pair, ask these first
- Which pharmacy makes it, and under what legal authority, given that neither drug can be compounded?
- Is the tesamorelin brand Egrifta, filled against a prescription in your name?
- Who checks your IGF-1 and blood sugar, and how often?
- What study supports the proposed combination rather than a claim based on either drug alone?
Legal options for the goals people name
Common goals discussed for this pair include less belly fat, a leaner build, or better sleep and recovery. Each has a legal place to start.
- Belly fat or weight: tesamorelin's label says it is not indicated for weight-loss management. GLP-1 programs are the legal options most people compare; see our metabolic shortlist.
- Muscle or body composition: tesamorelin has limited muscle and body-composition evidence, including a study in older adults outside HIV, as does tesamorelin build muscle shows. Start with our body composition shortlist.
- Sleep and recovery: sleep wasn't an outcome in the trials above. See our sleep and recovery shortlist.
If growth-hormone support is the real goal, sermorelin is the legal relative. It's prescribed as a compounded drug; how to get sermorelin covers the route, and sermorelin and ipamorelin together covers the other pairing you'll see.